Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 196.57

+4.0%

Jan 14 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: shasta23 who wrote (17868)	3/25/1998 8:31:00 PM
From: Henry Niman	Read Replies (2) of 32384

Stefan, I expect quite a bit of upcoming news. In the next few days LGND should announce the NDA filing as well as a milestone payment associated with AHP filing an IND for TSE for osteoporosis. Since LGND has final International Phase III data for the NDA, I expect a press release on that also (and I expect the data to be very good). On April 7 LGND will present their oral Panretin data for KS at an AIDS meeting sponsored by the AIDS Consortium. Later next month LGND will be presenting at UBS in Europe. I think that the NDA will bring some new analysts on board. I expect Raymond James to re-initiate coverage and I would not be at all surprised to see Merrill Lynch re-initiate coverage also. I suspect that other major brokerage houses are finializing their reports and their new coverage will bring in new buyers. I also think that there are big boys (institutions) on the sidelines who will come on board big time when the price begins to take off on heavy volume. There is much more news to follow. A new alliance or two would also come as no surprise. In fact I would be surprised if one or two were not announced fairly soon. LGND will be at ASCO in May as well as at the London branch of H&Q. In June they (and the AIDS Consortium) will be presenting big time at the International AIDS Conference in Geneva. I expect final Targretin topical and oral data for CTCL to also come out around the middle of the year as well as LLY to move into diabetes clinicals with Targretin and LGD1268 (or LGD1324). In summary, I expect news to come out fast a furious, which will make investors sit up and take note. The positive clinicals will again be in stark contrast to the rather steady diet of disappointing clinicals generated by others. Investors will begin to focus, which will be a major plus for Ligand.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next